Company / R&D Expense
BICYCLE THERAPEUTICS PLC R&D Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$240.3M
FY2025
5-year range
$44.9M / $240.3M
FY2021-FY2025
Trend
+38.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 6 consecutive years, from $26M in FY2019 to $240M in FY2025.
Based on SEC 10-K filings.
$240M in FY2025 with a 5-year CAGR of +48.6%.
Improved from $156M to $240M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +43.3%
- 5-Year CAGR
- +48.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- BICYCLE THERAPEUTICS PLC's r&d expense has grown for 6 consecutive years.
- 5-year CAGR of +48.6%, indicating consistent growth.
- In FY2025, r&d expense increased 38.9% year-over-year.
- Lowest r&d expense in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.98 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $240.3M | +38.9% |
| FY2024 | $173.0M | +10.5% |
| FY2023 | $156.5M | +91.8% |
| FY2022 | $81.6M | +81.8% |
| FY2021 | $44.9M | +35.4% |
| FY2020 | $33.1M | +29.8% |
| FY2019 | $25.5M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026